Quintrio
Home

SERVICES-MEDICAL LABORATORIES

Natera, Inc. Common Stock

NTRA

Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.

Last trade $284.61
Day change -$3.87 (-1.34%)
Day range $277.49 – $308.46
Volume 1,510,446
Market cap $41.83B

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$41.83B
Price / earnings
—
Price / book
22.37×
Price / sales
14.38×
EV / sales
14.03×
EV / EBITDA
-221.02×

Profitability

Earnings per share
-$1.14
Return on assets
-6%
Return on equity
-8.82%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0.04×
Current ratio
2.81×
Quick ratio
2.66×
Cash ratio
1.79×

Cash flow

Price / cash flow
196.59×
Price / free cash flow
797.28×
Free cash flow
$52.47M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for NTRA, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$793.98M$752.75M$696.64M$665.5M$592.18M$546.6M$501.83M$476.06M
Cost of revenue$280.51M$267.56M$245.81M$220.07M$207.8M$200M$185.07M$176.42M
Gross profit$513.47M$485.19M$450.83M$445.43M$384.38M$346.6M$316.77M$299.64M
Selling, general and administrative$333.66M$327.2M$327.94M$291.3M$308.55M$310.55M$266.86M$234.92M
Research and development$242.43M$228.07M$210.7M$175.19M$173.41M$146.43M$129.08M$129.46M
Total operating expenses$581.8M$560.98M$544.35M$468.21M$481.96M$456.98M$395.94M$364.38M
Operating income-$68.32M-$75.79M-$93.52M-$22.79M-$97.58M-$110.37M-$79.18M-$64.74M
Interest expense-$903K-$890K-$892K-$991K-$1.05M-$1.03M-$1.01M-$1.29M
Income before taxes-$59.61M-$67.23M-$84.81M-$13.33M-$87.34M-$100.66M-$66.76M-$55.13M
Income taxes$299K-$261K$283K-$60.58M$207K$275K$173K-$1.36M
Net income-$59.91M-$66.97M-$85.09M$47.26M-$87.54M-$100.94M-$66.94M-$53.77M
Net income attributable to common shareholders-$59.91M-$66.97M-$85.09M$47.1M-$87.54M-$100.94M-$66.94M-$56.09M
EBITDA-$46.36M-$54.6M-$73.29M-$10.41M-$87.28M-$100.51M-$69.94M-$56.95M
Basic earnings per share-$0.42-$0.47-$0.60$0.34-$0.64-$0.74-$0.50-$0.43
Diluted earnings per share-$0.42-$0.47-$0.60$0.34-$0.64-$0.74-$0.50-$0.43

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

Natera Q3 Earnings Call Highlights $6B Target & Raised 2026 Outlook

Natera (NTRA) raised its 2026 revenue guidance to $3.005-$3.035B from $2.850-$2.910B, driven by 56% year-over-year growth in Signatera testing volume to 316,000 units. Incoming CEO Solomon Moshkevich outlined an ambitious $6B annual revenue target by 2029, supported by MRD testing expansion, international growth, and pharmaceutical partnerships. The company reported Q3 2026 revenues of $794M (34.1% growth) but posted a wider-than-expected adjusted loss of 39 cents per share. Management expanded reimbursement coverage and advanced clinical trials while maintaining a 64%-66% gross margin guidance.

Zacks Investment Research

NTRA Q3 Loss Wider Than Expected, Revenues Beat, '26 Sales View Up

Natera (NTRA) reported Q3 2026 results with adjusted EPS loss of 39 cents missing estimates, but revenues of $794 million beat expectations with 34.1% year-over-year growth. Oncology test volumes surged 60.9% and MRD testing showed strong momentum. The company raised its 2026 revenue guidance to $3.005-$3.035 billion and maintained positive cash flow expectations, though operating losses remain a concern.

The Motley Fool

Decoding Healthcare ETFs: Different Sectors, Different Strategies

The article compares two healthcare ETFs: RSPH (Invesco S&P 500 Equal Weight Healthcare ETF) and XBI (State Street SPDR S&P Biotech ETF). RSPH offers broader healthcare sector diversification with lower volatility and higher dividend yield (0.56%), while XBI provides concentrated biotech exposure with higher short-term returns (39.6% 1-year) but steeper drawdowns (53.2% max). RSPH is recommended for conservative investors seeking stability, while XBI suits those with higher risk tolerance seeking biotech-specific growth.

Zacks Investment Research

Natera (NTRA) Reports Q3 Loss, Beats Revenue Estimates

Natera (NTRA) reported a quarterly loss of $0.39 per share, significantly worse than the consensus estimate of $0.17 loss, representing a -129.41% earnings surprise. While the company beat revenue expectations at $793.98 million versus estimates, it has only surpassed EPS estimates once in the last four quarters. The stock received a Zacks Rank #4 (Sell) rating due to unfavorable estimate revision trends, suggesting underperformance ahead despite the stock's 70.7% year-to-date gain.

Zacks Investment Research

Caris Life Sciences,?Inc. (CAI) Q3 Earnings and Revenues Top Estimates

Caris Life Sciences reported Q3 2026 earnings of $0.05 per share, beating consensus estimates of $0.03, with a 66.67% earnings surprise. Revenues reached $275.36 million, surpassing estimates by 9.75% and up from $216.83 million year-over-year. The company has beaten consensus estimates for four consecutive quarters. However, the stock received a Zacks Rank #3 (Hold) rating, suggesting near-term performance in line with the market.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.